RETRACTED: Meta-analysis:: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease (Retracted Article. See vol 19, p 145, 2004)

被引:70
作者
Cremonini, F
Di Caro, S
Delgado-Aros, S
Sepulveda, A
Gasbarrini, G
Gasbarrini, A
Camilleri, M
机构
[1] Mayo Clin & Mayo Fdn, Clin Enter Neurosci Translat & Epidemiol Res Prog, Rochester, MN 55902 USA
[2] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA
[3] Gemelli Hosp, Rome, Italy
关键词
D O I
10.1046/j.1365-2036.2003.01665.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The relationship between Helicobacter pylori infection and its treatment and gastro-oesophageal reflux disease (GERD) is controversial. Aims: To establish if H. pylori infection is associated with the presence of GERD and if anti-H. pylori treatment leads to de novo GERD or rebound/exacerbation of GERD. Methods: A search of MEDLINE and EMBASE databases was made. Pooled odds ratios (OR) were calculated for de novo GERD and rebound/exacerbated GERD after anti-H. pylori therapy in case-control studies and in therapeutic trials. Results: Fourteen case-control studies and 10 clinical trials were included. Among case-control studies, pooled OR for the association between H. pylori negative status and GERD was 1.34 [95% confidence interval (CI) 1.15-1.55]. Among therapeutic trials, pooled OR for the association anti-H. pylori therapy - GERD was 2.54 (95% CI 1.92-3.37). The OR for de novo GERD was 3.25 (95% CI 2.09-5.33), and for rebound/exacerbated GERD was 2.39 (95% CI 1.75-3.34). Associations were higher among Asian studies than among North American and European studies. Conclusions: This meta-analysis shows significant association between absence of H. pylori infection and GERD symptoms, and a positive association between anti-H. pylori therapy and occurrence of both de novo and rebound/exacerbated GERD. The significance of these associations appears to have been inflated by the effect of single trials and by geographical variations.
引用
收藏
页码:279 / 289
页数:11
相关论文
共 53 条
[1]   Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status:: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine [J].
Adamek, RJ ;
Behrendt, J ;
Wenzel, C .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2001, 13 (07) :811-817
[2]   Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease [J].
Befrits, R ;
Sjöstedt, S ;
Ödman, B ;
Sörngård, H ;
Lindberg, G .
HELICOBACTER, 2000, 5 (04) :202-205
[3]  
Boixeda D, 1995, MED CLIN-BARCELONA, V105, P774
[4]   How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology [J].
Calam, J ;
Gibbons, A ;
Healey, ZV ;
Bliss, P ;
Arebi, N .
GASTROENTEROLOGY, 1997, 113 (06) :S43-S49
[5]   PREVALENCE OF CAMPYLOBACTER-PYLORI IN ESOPHAGITIS, GASTRITIS, AND DUODENAL DISEASE [J].
CHENG, EH ;
BERMANSKI, P ;
SILVERSMITH, M ;
VALENSTEIN, P ;
KAWANISHI, H .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (06) :1373-1375
[6]  
Csendes A, 1997, Dis Esophagus, V10, P38
[7]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[8]   Opposing time trends of peptic ulcer and reflux disease [J].
El-Serag, HB ;
Sonnenberg, A .
GUT, 1998, 43 (03) :327-333
[9]   Corpus gastritis is protective against reflux oesophagitis [J].
El-Serag, HB ;
Sonnenberg, A ;
Jamal, MM ;
Inadomi, JM ;
Crooks, LA ;
Feddersen, RM .
GUT, 1999, 45 (02) :181-185
[10]   Helicobacter pylori infection and chronic gastric acid hyposecretion [J].
ElOmar, EM ;
Oien, K ;
ElNujumi, A ;
Gillen, D ;
Wirz, A ;
Dahill, S ;
Williams, C ;
Ardill, JES ;
McColl, KEL .
GASTROENTEROLOGY, 1997, 113 (01) :15-24